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Summary
Perampanel is an adjunctive treatment for epilepsy that works through the direct
inhibition of AMPA receptors. The same molecular mechanism has recently been
shown for a fatty acid, decanoic acid, prescribed in the medium chain triglyceride
ketogenic diet for the treatment of patients with drug‐resistant epilepsy. Because
each compound has been proposed to act through a distinct AMPA receptor bind-
ing site, we predicted that perampanel and decanoic acid would act synergistically
against AMPA receptors and, consequently, seizures. Here, we show a synergistic
interaction between perampanel and decanoic acid in direct AMPA receptor inhi-
bition, in an ex vivo model of seizure activity, and against seizure‐induced activ-
ity in human brain slices. These data support a potential role for combination
treatment using perampanel and dietary decanoic acid to provide enhanced seizure
control.
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1 | INTRODUCTION
Perampanel (Fycompa) is a noncompetitive AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antag-
onist and is an adjunctive treatment for partial‐onset and
primary generalized tonic–clonic seizures.1 However, it has
dose‐dependent behavioral side effects, thereby limiting its use
in some patients.2 Although the binding site for perampanel has
been well characterized on AMPA receptors,3 there is little
information on its subtype specificity and potential synergistic
action with other AMPA receptor antagonists.
The medium chain triglyceride (MCT) ketogenic diet
provides a nonpharmacologic treatment for patients with
drug‐resistant epilepsy.4 Ketone generation was considered
necessary for seizure control5; however, recent studies have
shown a direct antiseizure effect of medium chain fatty
acids,6–8 likely to be through noncompetitive inhibition of
AMPA receptors by decanoic acid (DA).6 Because in silico
analysis suggests that DA binds to the AMPA receptor at a
site distinct to that of perampanel,8 we hypothesized that
combined perampanel and DA dosing will result in syner-
gistic inhibition of AMPA receptors and enhanced seizure
control.
2 | METHODS
2.1 | AMPA receptor oocyte
electrophysiology
Recordings of recombinant AMPA receptor inward currents
from Xenopus oocytes have been described previously.8
Perampanel was purchased from Apexmol Technology Co.
Ltd. (Beijing, China).
2.2 | Rat Hippocampal pentylenetetrazole
seizure‐like activity analysis
Seizure‐like activity was induced in rat entorhinal cortex‐
hippocampal slices as described previously8; perampanel
(0, 100, or 500 nmol/L) and DA (increasing concentrations
at 10 minute intervals) were then applied. The frequency of
the discharges was measured at minute intervals, averaged
every 5 minutes, and normalized to baseline. IC50 values
(half maximal inhibitory concentration) were calculated
using a Hill plot with statistical analysis by one‐way analy-
sis of variance (ANOVA) with Dunnett's post hoc test.
2.3 | In vitro human brain slice studies
Neocortical human brain slices were derived from patients
undergoing elective neurosurgical resection of a neoplasm,
where 7 of 8 had a history of epileptic seizures. Preopera-
tive informed consent was obtained for the use of resected
brain tissue. This study was approved by the Newcastle
and North Tyneside 2 Research Ethics Committee (06/
Q1003/51), with clinical governance approved by the New-
castle Upon Tyne Hospitals National Health Service (NHS)
Trust (CM/PB/3707). A human neocortical slice (450 μm)
preparation was used as has been described previously.9
Statistical analysis was performed using a Mann‐Whitney
test.
3 | RESULTS
3.1 | Direct inhibition of AMPA receptors by
perampanel and decanoic acid
Prior to the investigation of a synergistic effect between
perampanel and decanoic acid, we first investigated the
effect of perampanel on currents elicited by glutamate
(100 μmol/L) application to Xenopus laevis oocytes
expressing 2 AMPA receptor subunit combinations,
GluA1/2 or 2/3. These 2 subunit combinations are the most
commonly found combinations in the hippocampus.9 Per-
ampanel inhibited AMPA receptor currents with an IC50 of
8.11 μmol/L against GluA2/3 (SEM [standard error of the
mean] 2.05) and 6.27 μmol/L against GluA1/2 (SEM 1.02)
(Figure S1A,B) in a noncompetitive manner (Figure S1C).
Perampanel reduced maximal responses to 75.2% (at
2.5 μmol/L) and 16.9% (at 5 μmol/L) showing, for the first
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time, the direct inhibition of AMPA receptors by peram-
panel through noncompetitive inhibition without subunit
specificity.
Recent studies propose distinct binding sites for peram-
panel and DA on AMPA receptors,3,6 with perampanel bind-
ing at the S1‐M1 and S2‐M4 linker3 and DA binding to the
M3 region.6 To confirm this, we expressed a GluA3 mutant
resistant to the AMPA receptor antagonist GYKI,3 and
assessed it for sensitivity to perampanel and DA (Fig-
ure S1D). Perampanel (20 μmol/L) reduced the wild‐type
AMPA receptor (GluA3) glutamate‐induced currents by
94.7%, but the mutant receptor currents by only 54.3%
(P < 0.0001). In contrast, DA (1 mmol/L) reduced both cur-
rents by 74.5% (SEM 6.4) and 72.8% (SEM 0.3), respectively,
strongly supporting the proposed distinct sites of action.
The existence of distinct AMPA receptor binding sites for
DA and perampanel raises the possibility of synergism;
therefore we tested AMPA receptor sensitivity to DA at 2
concentrations of perampanel (1 and 4 μmol/L) (Figure 1A,
B,C). For GluA2/3, the IC50 for DA decreased from
0.52 mmol/L (no perampanel) to 0.15 mmol/L (1 μmol/L
perampanel) or 0.12 mmol/L (4 μmol/L perampanel)
(P < 0.0001). For GluA1/2 the IC50 for DA decreased from
1.16 mmol/L (no perampanel) to 0.21 mmol/L (1 μmol/L
perampanel) or 0.10 mmol/L (4 μmol/L perampanel)
(P < 0.0001). Repeating this approach using perampanel
with 2 concentrations of DA (50 and 100 μmol/L) (Fig-
ure 1D,E,F) also showed a significant increase in the potency
of perampanel, decreasing IC50 values from 8.1 μmol/L (no
DA) to 1.7 and 1.6 μmol/L in the presence of DA at 50 and
100 μmol/L, respectively, in GluA2/3 and from 6.2 μmol/L
in GluA1/2 to 2.1 and 2.2 μmol/L, respectively (both
P < 0.0001). These results imply synergistic inhibition of
AMPA receptors by DA and perampanel.
To validate a synergistic effect of both perampanel and
DA on AMPA receptor currents, an isobolographic analysis
was used. This approach can distinguish between additive
and synergistic effects of 2 compounds with similar effects
(Figure 1G,H). In this analysis, the isobolic line represents
additive effects of the compounds against both GluA1/2
and GluA2/3 receptors. From results provided here, combi-
natory treatment with perampanel and DA provides points
at fixed ratios of each compound that lie below the isobolic
line, indicating a synergistic effect. This analysis, therefore,
supports a direct synergistic effect of perampanel and DA
against AMPA receptors.
3.2 | Effects of perampanel and decanoic
acid on an ex vivo (animal) seizure model
To investigate a synergistic effect in controlling seizure‐like
activity and to avoid the confounders of systemic metabo-
lism or pharmacokinetic interactions, we then investigated
the effects of combinatory perampanel and DA on PTZ‐
induced seizure‐like activity in rat hippocampal slices. In
these experiments, increasing DA concentrations reduced
epileptiform activity at 300 μmol/L with a block at
1000 μmol/L (Figure 2A,B), consistent with earlier data.6
Repeating of the assay with added perampanel (100 and
500 nmol/L) with data normalized to perampanel alone,
showed that DA (10 μmol/L) combined with perampanel
(100 nmol/L) caused a significant reduction in seizure
activity from 95.6% (confidence interval [CI] 81 to 110) in
the absence of DA to 76.8% (CI 63‐90, P = 0.048) in its
presence, and a block at 600 μmol/L. A similar activity is
also shown at higher perampanel (500 nmol/L) concentra-
tions, reducing baseline (10 μmol/L) inhibition to 69.6% (CI
53‐86, P = 0.015). These data also demonstrate a reduced
IC50 for DA from 352 μmol/L (CI 200‐621) to 196 μmol/L
(145‐264) and 122 μmol/L (49‐302, P = 0.0252) at 100
and 500 nmol/L, respectively.
3.3 | Effects of perampanel and decanoic
acid on ex vivo human brain slice seizure
activity
We then investigated the translational potential of the
observed synergism between perampanel and DA in reduc-
ing epileptiform activity in human brain explants.10 Slices
were obtained from 8 patients undergoing elective neuro-
surgery for removal of intraaxial neoplasms (Figure 2C).
Using a proconvulsant artificial cerebrospinal fluid, epilep-
tiform activity was induced and the impact of DA, peram-
panel, and combinatory treatment was examined
(Figure 2D,E). Baseline epileptiform activity had a mean
(95% CI) area power of 1690 μV2 (CI 1192‐2191 μV2;
n = 21). In the presence of DA (100 μmol/L) alone the
activity was reduced (1088 μV2, CI: 393‐1782 μV2; n = 8)
but this difference was not statistically significant
(P = 0.1390). The application of perampanel (0.5 μmol/L)
alone also did not have a significant effect (P = 0.7554)
on activity when compared to baseline activity (1621 μV2,
CI: 681‐2562 μV2; n = 10). In contrast, the concurrent
application of DA and perampanel significantly
(p < 0.0001) reduced the area power of epileptiform activ-
ity (144.7 μV2, CI: 15.6‐274 μV2; n = 11) with a virtual
abolition of the pathologic network LFP (local field poten-
tial) activity. In addition, the combination of compounds
had a significantly greater effect when compared with both
DA (P = 0.0005) and perampanel (P = 0.0002) alone.
4 | DISCUSSION
These data confirm that combinatory use of DA and per-
ampanel is effective in directly reducing AMPA receptor
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generated currents and in reducing PTZ‐induced seizure‐
like activity in hippocampal slice preparations. Further-
more, this synergistic effect is also evident with epilepti-
form activity generated in resected human neocortical
tissue, emphasizing the translational potential for this thera-
peutic approach in patients with epilepsy.
Mechanistic studies of perampanel inhibition of AMPA
receptors have been complicated by low solubility, non-
standard concentration response curves, and variable litera-
ture. Plasma concentrations of perampanel have been
reported to vary between 1.06 and 3.26 μmol/L.11 Our data
indicate that perampanel directly inhibits AMPA receptor
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FIGURE 2 Synergistic activity of perampanel and decanoic acid (DA) in rodent and human seizure models. A, Epileptiform (paroxysmal) activity
was induced in rat entorhinal cortex‐hippocampal slices by application of pentylenetetrazole (PTZ; 2 mmol/L) and [K+] (to 6 mmol/L) and recorded
over time at fixed perampanel and increasing DA concentration. B, Epileptiform activity was normalized to activity in absence or presence of each
concentration (100 and 500 nmol/L) and shown at variable DA concentrations. Insert shows DA IC50 data for epileptiform activity with perampanel.
Data are from 7‐8 slices for each group. C, Summary of clinical detail pertaining to tissues used in this study. DNET, dysembryoplastic neuroepithelial
tumor; LEV, levetiracetam; LTG, lamotrigine. D, Epileptic activity was induced in human neocortical slices by the perfusion of modified cerebrospinal
fluid (0.25 mmol/LMg2+ and 8 mMK+), and the example traces demonstrate the impact of DA (0.1 mmol/L) alone, perampanel (0.5 mmol/L) alone,
and DA and perampanel on pathologic network activity. E, The area power (0.1‐100 Hz) of epileptic activity for each of the experimental conditions.
Scale bars represent 1 mV and 5 minutes (D) * P < 0.05; *** P < 0.001; **** P ≤ 0.0001
FIGURE 1 Characterization of direct synergistic inhibition of AMPA receptors by perampanel and decanoic acid (DA). AMPA (GluA2/3,
GluA1/2, or GluA3) receptors were expressed in Xenopus oocytes, and perfused with L‐glutamate (100 μmol/L) and the indicated compound,
unless stated otherwise. Currents were recorded using TEVC. A, Representative current traces of inhibitory dose‐response curves for DA on
GluA2/3 receptors at 1 or 4 μmol/L perampanel. Dose‐response inhibition curves for DA at 1 or 4 μmol/L perampanel on (B) GluA2/3 and (C)
GluA1/2 receptors. Points were normalized to maximal response to L‐glutamate and solvent, 1 μmol/L perampanel, or 4 μmol/L perampanel and
represent means and standard error of the mean (SEM) of 8‐13 readings. Inserts show respective IC50 values in the presence of perampanel.
D, Representative current traces of inhibitory dose‐response curves for perampanel on GluA2/3 receptors at 50 to 100 μmol/L DA. Dose‐response
inhibition curves for perampanel at 50 and 100 μmol/L DA on (E) GluA2/3 and (F) GluA1/2 receptors. Points were normalized to maximal
response to L‐glutamate with solvent, 50 and 100 μmol/L DA and represent means and SEM of 8‐13 readings. Inserts show respective
perampanel IC50 values in the presence of DA. Scale bars correspond to 60 and 75 nA for 1 and 4 μmol/L perampanel, respectively (A) and 200
and 50nA for 50 and 100 μmol/L DA, respectively (D). G, H, Isobolic analysis of the effect of perampanel and DA, showing the isobole
(straight line) representing combinatorial doses that are additive. Data points, shown in the line below the isobole, indicate a synergistic effect
between each compound at that dose combination *** P<0.001; **** P ≤ 0.0001
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currents with IC50 values of 5.1‐6.2 μmol/L, similar to that
shown using native rat and human cerebellar AMPA receptors
microtransported into Xenopus oocytes (2.6‐5.8 μmol/L12).
Why this is so different from IC50 values recorded from rat
neurons (60‐93 nmol/L13,14) is unclear, but may be due to
the presence of other proteins in rat neurons.
Levels of DA have also been monitored in both human
and animal models. In the blood of patients on the MCT
ketogenic diet, the concentration of DA averages
157 μmol/L.15,16 In rodent models, the ratio of DA in
blood plasma to brain is around 0.7,17 and extrapolating
this to the human brain suggests that DA is likely to be
present at around 110 μmol/L. Our data indicate that
100 μmol/L DA results in a 3‐fold increase in the inhibi-
tion of the AMPA receptor by perampanel, which translates
to an even greater impact on seizure activity. In a clinical
setting, these observations suggest that, with dietary
decanoic acid, a reduction in perampanel dose to, for
example, 2‐4 mg/d, may provide effective seizure control.
These data support the synergistic inhibition of AMPA
receptors through combinatory treatment with perampanel
and dietary medium chain triglycerides containing DA that
may provide both improved seizure control and reduced
side effects in patient populations.
In the validation of new approaches for the treatment of
epilepsy, in vivo animal studies are often used. The difficulty
with in vivo analysis for this study is that metabolism of
decanoic acid (or the MCT diet) provides a significant prob-
lem because rodents have a much increased metabolic rate
(compared to humans). This is likely to lead to the rapid
metabolism of decanoic acid in vivo, and thus does not ele-
vate brain levels for a sufficient time following a single dose.
Two in vivo studies of medium chain fatty acids in seizure
control have used either 10‐day MCT ketogenic diets18 or
large single bolus delivery of these fats17 to analyze brain
and blood levels. Due to this rapid metabolic effect, the only
way to monitor synergistic effects related to decanoic acid
and perampanel using an in vivo rodent model would be to
establish IC50 values for perampanel, in animals under stan-
dard dietary conditions or following maintenance on the
MCT diet. However, this approach would not distinguish
between potential synergy caused by decanoic acid or the
resulting ketones provided by dietary treatment. Thus, since
both MCT diets and perampanel are currently used in clini-
cal treatment, future studies would need to investigate thera-
peutic outcomes in patient groups on an MCT diet with
additionally prescribed perampanel.
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